Isolevuglandin adducts in disease

Antioxidants and Redox Signaling

Volumn 22, Issue 18, 2015, Pages 1703-1718

  Salomon, Robert G ^a   Bi, Wenzhao ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DERIVATIVE; AMYLOID BETA PROTEIN[1-42]; CHOLESTANETRIOL 26 MONOOXYGENASE; ENDOPEROXIDE; FREE RADICAL; ISOLEVUGLANDIN; LIPID; LYSINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG; AMYLOID; DNA BINDING PROTEIN; PROSTAGLANDIN E; PROTEIN BINDING; PYRROLIDINE DERIVATIVE; TUBULIN; UNSATURATED FATTY ACID;

AGE RELATED MACULAR DEGENERATION; ALCOHOL LIVER DISEASE; ALLERGY; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ATHEROSCLEROSIS; CELL ADHESION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA CROSS LINKING; END STAGE RENAL DISEASE; ENDOTHELIUM CELL; GLAUCOMA; HEART ARRHYTHMIA; HUMAN; IN VITRO STUDY; INFECTION; INFLAMMATION; ISOMER; MONOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; OLIGOMERIZATION; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN DNA INTERACTION; PROTEIN PROTEIN INTERACTION; REVIEW; SYNTHESIS; THROMBOSIS; ANIMAL; BLOOD BRAIN BARRIER; CHEMISTRY; METABOLISM; MITOCHONDRION; OXIDATIVE STRESS; PATHOLOGY;

AMYLOID; ANIMALS; BLOOD-BRAIN BARRIER; DNA-BINDING PROTEINS; FATTY ACIDS, UNSATURATED; HUMANS; INFLAMMATION; MITOCHONDRIA; OXIDATIVE STRESS; PHOSPHATIDYLETHANOLAMINES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS E; PROTEIN BINDING; PYRROLIDINES; TUBULIN;

EID: 84930670117     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.6154     Document Type: Review

References (102)

1. Amarnath V, Amarnath K, Amarnath K, Davies S, and Roberts LJ, 2nd. Pyridoxamine: an extremely potent scavenger of 1, 4-dicarbonyls. Chem Res Toxicol 17: 410-415, 2004.
2. Bernoud-Hubac N, Alam DA, Lefils J, Davies SS, Amarnath V, Guichardant M, Roberts LJ, 2nd, and Lagarde M. Low concentrations of reactive gamma-ketoaldehydes prime thromboxane-dependent human platelet aggregation via p38-MAPK activation. Biochim Biophys Acta 1791: 307-313, 2009.
3. Bernoud-Hubac N, Davies SS, Boutaud O, Montine TJ, and Roberts LJ, 2nd. Formation of highly reactive gammaketoaldehydes (neuroketals) as products of the neuroprostane pathway. J Biol Chem 276: 30964-30970, 2001.
4. Bernoud-Hubac N, Fay LB, Armarnath V, Guichardant M, Bacot S, Davies SS, Roberts LJ, 2nd, and Lagarde M. Covalent binding of isoketals to ethanolamine phospholipids. Free Radic Biol Med 37: 1604-1611, 2004.
5. Bernoud-Hubac N and Roberts LJ, 2nd. Identification of oxidized derivatives of neuroketals. Biochemistry 41: 11466-11471, 2002.
6. Boutaud O, Brame CJ, Chaurand P, Li J, Rowlinson SW, Crews BC, Ji C, Marnett LJ, Caprioli RM, Roberts LJ, 2nd, and Oates JA. Characterization of the lysyl adducts of prostaglandin H-synthases that are derived from oxygenation of arachidonic acid. Biochemistry 40: 6948-6955, 2001.
7. Boutaud O, Li J, Chaurand P, Brame CJ, Marnett LJ, Roberts LJ, and Oates JA. Oxygenation of arachidonic acid by cyclooxygenases generates reactive intermediates that form adducts with proteins. Adv Exp Med Biol 500: 133-137, 2001.
8. Boutaud O, Li J, Zagol I, Shipp EA, Davies SS, Roberts LJ, 2nd, and Oates JA. Levuglandinyl adducts of proteins are formed via a prostaglandin H2 synthase-dependent pathway after platelet activation. J Biol Chem 278: 16926-16928, 2003.
9. Boutaud O, Montine TJ, Chang L, Klein WL, and Oates JA. PGH2-derived levuglandin adducts increase the neurotoxicity of amyloid beta1-42. J Neurochem 96: 917-923, 2006.
10. Boutaud O, Ou JJ, Chaurand P, Caprioli RM, Montine TJ, and Oates JA. Prostaglandin H2 (PGH2) accelerates formation of amyloid beta1-42 oligomers. J Neurochem 82: 1003-1006, 2002.
11. Boutaud O, Zagol-Ikapitte I, Amarnath V, Yermalitsky V, Andreasson KI, Montine TJ, and Oates JA. Targeting cyclooxygenase-derived levuglandins as potentially novel therapeutic approaches to Alzheimer's disease. J Alz Assoc 2: S599, 2006.
12. Brame CJ, Boutaud O, Davies SS, Yang T, Oates JA, Roden D, and Roberts LJ, 2nd. Modification of proteins by isoketal-containing oxidized phospholipids. J Biol Chem 279: 13447-13451, 2004.
13. Brame CJ, Salomon RG, Morrow JD, and Roberts LJ, 2nd. Identification of extremely reactive gamma-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts. J Biol Chem 274: 13139-13146, 1999.
14. Carrier EJ, Amarnath V, Oates JA, and Boutaud O. Characterization of covalent adducts of nucleosides and DNA formed by reaction with levuglandin. Biochemistry 48: 10775-10781, 2009.
15. Carrier EJ, Zagol-Ikapitte I, Amarnath V, Boutaud O, and Oates JA. Levuglandin forms adducts with histone h4 in a cyclooxygenase-2-dependent manner, altering its interaction with DNA. Biochemistry 53: 2436-2441, 2014.
16. Charvet C, LiaoWL, Heo GY, Laird J, Salomon RG, Turko IV, and Pikuleva IA. Isolevuglandins and mitochondrial enzymes in the retina: mass spectrometry detection of posttranslational modification of sterol-metabolizing CYP27A1. J Biol Chem 286: 20413-20422, 2011.
17. Charvet CD, Laird J, Xu Y, Salomon RG, and Pikuleva IA. Posttranslational modification by an isolevuglandin diminishes activity of the mitochondrial cytochrome P450 27A1. J Lipid Res 54: 1421-1429, 2013.
18. Charvet CD, Saadane A, Wang M, Salomon RG, Brunengraber H, Turko IV, and Pikuleva IA. Pretreatment with pyridoxamine mitigates isolevuglandin-associated retinal effects in mice exposed to bright light. J Biol Chem 288: 29267-29280, 2013.
19. Davies SS, Amarnath V, Montine KS, Bernoud-Hubac N, Boutaud O, Montine TJ, and Roberts LJ, 2nd. Effects of reactive gamma-ketoaldehydes formed by the isoprostane pathway (isoketals) and cyclooxygenase pathway (levuglandins) on proteasome function. FASEB J 16: 715-717, 2002.
20. Davies SS, Bodine C, Matafonova E, Pantazides BG, Bernoud-Hubac N, Harrison FE, Olson SJ, Montine TJ, Amarnath V, and Roberts LJ, 2nd. Treatment with a gamma-ketoaldehyde scavenger prevents working memory deficits in hApoE4 mice. J Alzheimers Dis 27: 49-59, 2011.
21. Davies SS, Brantley EJ, Voziyan PA, Amarnath V, Zagol-Ikapitte I, Boutaud O, Hudson BG, Oates JA, and Roberts LJ, 2nd. Pyridoxamine analogues scavenge lipid-derived gamma-ketoaldehydes and protect against H2O2-mediated cytotoxicity. Biochemistry 45: 15756-15767, 2006.
22. Davies SS, Talati M, Wang X, Mernaugh RL, Amarnath V, Fessel J, Meyrick BO, Sheller J, and Roberts LJ, 2nd. Localization of isoketal adducts in vivo using a single-chain antibody. Free Radic Biol Med 36: 1163-1174, 2004.
23. Ding WX, Ni HM, DiFrancesca D, Stolz DB, and Yin XM. Bid-dependent generation of oxygen radicals promotes death receptor activation-induced apoptosis in murine hepatocytes. Hepatology 40: 403-413, 2004.
24. Evans TA, Siedlak SL, Lu L, Fu X, Wang Z, McGinnisWR, Fakhoury E, Castellani RJ, Hazen SL, Walsh WJ, Lewis AT, Salomon RG, Smith MA, Perry G, and Zhu X. The Autistic Phenotype Exhibits a Remarkably LocalizedModification of Brain Protein by Products of Free Radical-Induced Lipid Oxidation. Am J Biotech Biochem 4: 61-72, 2008.
25. Fogelman AM, Schechter I, Hokom M, Child JS, and Edwards PA. Malondialdehyde alteration of low-density lipoprotein leads to cholesterol accumulation in human monocyte-macrophages. Proc Natl Acad Sci USA 77: 2214-2218, 1980.
26. Fukuda K, Davies SS, Nakajima T, Ong BH, Kupershmidt S, Fessel J, Amarnath V, Anderson ME, Boyden PA, Viswanathan PC, Roberts LJ, 2nd, and Balser JR. Oxidative mediated lipid peroxidation recapitulates proarrhythmic effects on cardiac sodium channels. Circ Res 97: 1262-1269, 2005.
27. Garcia-Ovejero D, Arevalo-Martin A, Petrosino S, Docagne F, Hagen C, Bisogno T, Watanabe M, Guaza C, Di Marzo V, and Molina-Holgado E. The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiol Dis 33: 57-71, 2009.
28. Glenner GG and Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-890, 1984.
29. Gonzalo H, Brieva L, Tatzber F, Jove M, Cacabelos D, Cassanye A, Lanau-Angulo L, Boada J, Serrano JC, Gonzalez C, Hernandez L, Peralta S, Pamplona R, and Portero-Otin M. Lipidome analysis in multiple sclerosis reveals protein lipoxidative damage as a potential pathogenic mechanism. J Neurochem 123: 622-634, 2012.
30. Govindarajan B, Junk A, Algeciras M, Salomon RG, and Bhattacharya SK. Increased isolevuglandin-modified proteins in glaucomatous astrocytes. Mol Vis 15: 1079-1091, 2009.
31. Govindarajan B, Laird J, Salomon RG, and Bhattacharya SK. Isolevuglandin-modified proteins, including elevated levels of inactive calpain-1, accumulate in glaucomatous trabecular meshwork. Biochemistry 47: 817-825, 2008.
32. Govindarajan B, Laird J, Sherman R, Salomon RG, and Bhattacharya SK. Neuroprotection in glaucoma using calpain-1 inhibitors: regional differences in calpain-1 activity in the trabecular meshwork, optic nerve and implications for therapeutics. CNS Neurol Disord Drug Targets 7: 295-304, 2008.
33. Guo L, Amarnath V, and Davies SS. A liquid chromatography-tandem mass spectrometry method for measurement of N-modified phosphatidylethanolamines. Anal Biochem 405: 236-245, 2010.
34. Guo L, Chen Z, Amarnath V, and Davies SS. Identification of novel bioactive aldehyde-modified phosphatidylethanolamines formed by lipid peroxidation. Free Radic Biol Med 53: 1226-1238, 2012.
35. Guo L, Chen Z, Cox BE, Amarnath V, Epand RF, Epand RM, and Davies SS. Phosphatidylethanolamines modified by gamma-ketoaldehyde (gammaKA) induce endoplasmic reticulum stress and endothelial activation. J Biol Chem 286: 18170-18180, 2011.
36. Guo L and Davies SS. Bioactive aldehyde-modified phosphatidylethanolamines. Biochimie 95: 74-78, 2013.
37. Guo L, Gragg SD, Chen Z, Zhang Y, Amarnath V, and Davies SS. Isolevuglandin-modified phosphatidylethanolamine is metabolized by NAPE-hydrolyzing phospholipase D. J Lipid Res 54: 3151-3157, 2013.
38. Hazen SL, Heller J, Hsu FF, d'Avignon A, and Heinecke JW. Synthesis, isolation, and characterization of the adduct formed in the reaction of p-hydroxyphenylacetaldehyde with the amino headgroup of phosphatidylethanolamine and phosphatidylserine. Chem Res Toxicol 12: 19-27, 1999.
39. Hollyfield JG, Salomon RG, and Crabb JW. Proteomic approaches to understanding age-related macular degeneration. Adv Exp Med Biol 533: 83-89, 2003.
40. Hoppe G, Subbanagounder G, O'Neil J, Salomon RG, and Hoff HF. Macrophage recognition of LDL modified by levuglandin E2, an oxidation product of arachidonic acid. Biochim Biophys Acta 1344: 1-5, 1997.
41. Iimuro Y, Gallucci RM, Luster MI, Kono H, and Thurman RG. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 26: 1530-1537, 1997.
42. in t' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, and Stricker BH. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345: 1515-1521, 2001.
43. Iyer RS, Ghosh S, and Salomon RG. Levuglandin E2 crosslinks proteins. Prostaglandins 37: 471-480, 1989.
44. Jirousek MR, Murthi KK, and Salomon RG. Electrophilic levuglandin E2-protein adducts bind glycine: a model for protein crosslinking. Prostaglandins 40: 187-203, 1990.
45. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, and Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 6448-6453, 1998.
46. Li CM, Clark ME, Rudolf M, and Curcio CA. Distribution and composition of esterified and unesterified cholesterol in extra-macular drusen. Exp Eye Res 85: 192-201, 2007.
47. Li W, Laird JM, Lu L, Roychowdhury S, Nagy LE, Zhou R, Crabb JW, and Salomon RG. Isolevuglandins covalently modify phosphatidylethanolamines in vivo: detection and quantitative analysis of hydroxylactam adducts. Free Radic Biol Med 47: 15,39-1552, 2009.
48. Lopes UG, Erhardt P, Yao R, and Cooper GM. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 272: 12893-12896, 1997.
49. Masaki R, Saito T, Yamada K, and Ohtani-Kaneko R. Accumulation of phosphorylated neurofilaments and increase in apoptosis-specific protein and phosphorylated c-Jun induced by proteasome inhibitors. J Neurosci Res 62: 75-83, 2000.
50. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, and Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82: 4245-4249, 1985.
51. Murthi KK, Friedman LR, Oleinick NL, and Salomon RG. Formation of DNA-protein cross-links in mammalian cells by levuglandin E2. Biochemistry 32: 4090-4097, 1993.
52. Murthi KK, Salomon RG, and Sternlicht H. Levuglandin E2 inhibits mitosis and microtubule assembly. Prostaglandins 39: 611-622, 1990.
53. Nakajima T, Davies SS, Matafonova E, Potet F, Amarnath V, Tallman KA, Serwa RA, Porter NA, Balser JR, Kupershmidt S, and Roberts LJ, 3rd. Selective gammaketoaldehyde scavengers protect Nav1.5 from oxidantinduced inactivation. JMol Cell Cardiol 48: 352-359, 2010.
54. Nugteren DH and Christ-Hazelhof E. Chemical and enzymic conversions of the prostaglandin endoperoxide PGH2. Adv Prostaglandin Thromboxane Res 6: 129-137, 1980.
55. Nugteren DH and Hazelhof E. Isolation and properties of intermediates in prostaglandin biosynthesis. Biochim Biophys Acta 326: 448-461, 1973.
56. Nyilas R, Dudok B, Urban GM, Mackie K, Watanabe M, Cravatt BF, Freund TF, and Katona I. Enzymatic machinery for endocannabinoid biosynthesis associated with calcium stores in glutamatergic axon terminals. J Neurosci 28: 1058-1063, 2008.
57. Ohtani-Kaneko R, Takada K, Iigo M, Hara M, Yokosawa H, Kawashima S, Ohkawa K, and Hirata K. Proteasome inhibitors which induce neurite outgrowth from PC12h cells cause different subcellular accumulations of multiubiquitin chains. Neurochem Res 23: 1435-1443, 1998.
58. Okamoto Y, Morishita J, Tsuboi K, Tonai T, and Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 279: 5298-5305, 2004.
59. Panigrahi S, Ma Y, Hong L, Gao D, West XZ, Salomon RG, Byzova TV, and Podrez EA. Engagement of platelet toll-like receptor 9 by novel endogenous ligands promotes platelet hyperreactivity and thrombosis. Circ Res 112: 103-112, 2013.
60. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M, Finton PJ, Shan L, Febbraio M, Hajjar DP, Silverstein RL, Hoff HF, Salomon RG, and Hazen SL. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem 277: 38517-38523, 2002.
61. Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M, Finton PJ, Shan L, Gugiu B, Fox PL, Hoff HF, Salomon RG, and Hazen SL. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem 277: 38503-38516, 2002.
62. Poliakov E, Brennan ML, Macpherson J, Zhang R, Sha W, Narine L, Salomon RG, and Hazen SL. Isolevuglandins, a novel class of isoprostenoid derivatives, function as integrated sensors of oxidant stress and are generated by myeloperoxidase in vivo. FASEB J 17: 2209-2220, 2003.
63. Poliakov E, Meer SG, Roy SC, Mesaros C, and Salomon RG. Iso[7]LGD2-protein adducts are abundant in vivo and free radical-induced oxidation of an arachidonyl phospholipid generates this D series isolevuglandin in vitro. Chem Res Toxicol 17: 613-622, 2004.
64. Raz A, Kenig-Wakshal R, and Schwartzman M. Effect of organic sulfur compounds on the chemical and enzymatic transformations of prostaglandin endoperoxide H2. Biochim Biophys Acta 488: 322-329, 1977.
65. Rieder R and Bosshard HR. Comparison of the binding sites on cytochrome c for cytochrome c oxidase, cytochrome bc1, and cytochrome c1. Differential acetylation of lysyl residues in free and complexed cytochrome c. J Biol Chem 255: 4732-4739, 1980.
66. Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, Woods AS, Cotter RJ, Tuohy JM, Krafft GA, Bonnell BS, and Emmerling MR. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 271: 20631-20635, 1996.
67. Roychowdhury S, McMullen MR, Pritchard MT, Li W, Salomon RG, and Nagy LE. Formation of gammaketoaldehyde-protein adducts during ethanol-induced liver injury in mice. Free Radic Biol Med 47: 1526-1538, 2009.
68. Rudolf M, Malek G, Messinger JD, Clark ME, Wang L, and Curcio CA. Sub-retinal drusenoid deposits in human retina: organization and composition. Exp Eye Res 87: 402-408, 2008.
69. Salomon MF and Salomon RG. 2, 3-Dioxabicyclo-[2.2.1]heptane. The strained cyclic peroxide nucleus of prostaglandin endoperoxides. J Am Chem Soc 99: 3501-3503, 1977.
70. Salomon RG. Prostaglandin endoperoxide reaction mechanisms and the discovery of levuglandins. Accounts Chem Res 18: 294, 1985.
71. Salomon RG. Distinguishing levuglandins produced through the cyclooxygenase and isoprostane pathways. Chem Phys Lipids 134: 1-20, 2005.
72. Salomon RG. Levuglandins and isolevuglandins: stealthy toxins of oxidative injury. Antioxid Redox Signal 7: 185-201, 2005.
73. Salomon RG, Batyreva E, Kaur K, Sprecher DL, Schreiber MJ, Crabb JW, Penn MS, DiCorletoe AM, Hazen SL, and Podrez EA. Isolevuglandin-protein adducts in humans: products of free radical-induced lipid oxidation through the isoprostane pathway. Biochim Biophys Acta 1485: 225-235, 2000.
74. Salomon RG, Jirousek MR, Ghosh S, and Sharma RB. Prostaglandin endoperoxides 21. Covalent binding of levuglandin E2 with proteins. Prostaglandins 34: 643-656, 1987.
75. Salomon RG, Kaur K, and Batyreva E. Isolevuglandinprotein adducts in oxidized low density lipoprotein and human plasma: a strong connection with cardiovascular disease. Trends Cardiovasc Med 10: 53-59, 2000.
76. Salomon RG, Miller DB, Raychaudhuri SR, Avasthi K, Lal K, and Levison BS. Prostaglandin endoperoxides. 15. Asymmetric total synthesis of levuglandin E2. J Am Chem Soc 106: 8296-8298, 1984.
77. Salomon RG, Miller DB, Zagorski MG, and Coughlin DJ. Solvent induced fragmentation of prostaglandin endoperoxides. New aldehyde products from PGH2 and a novel intramolecular 1, 2-hydride shift during endoperoxide fragmentation in aqueous solution. J Am Chem Soc 106: 6049-6060, 1984.
78. Salomon RG, Salomon MF, and Coughlin DJ. Prostaglandin Endoperoxides. 6. A polar transition state in the thermal rearrangement of 2, 3-dioxabicyclo[2.2.1]heptane. J Am Chem Soc 100: 660-662, 1978.
79. Salomon RG, Subbanagounder G, O'Neil J, Kaur K, Smith MA, Hoff HF, Perry G, and Monnier VM. Levuglandin E2-protein adducts in human plasma and vasculature. Chem Res Toxicol 10: 536-545, 1997.
80. Salomon RG, Subbanagounder G, Singh U, O'Neil J, and Hoff HF. Oxidation of low-density lipoproteins produces levuglandin-protein adducts. Chem Res Toxicol 10: 750-759, 1997.
81. Santiard-Baron D, Lacoste A, Ellouk-Achard S, Soulie C, Nicole A, Sarasin A, and Ceballos-Picot I. The amyloid peptide induces early genotoxic damage in human preneuron NT2. Mutat Res 479: 113-120, 2001.
82. Schmidley JW, Dadson J, Iyer RS, and Salomon RG. Brain tissue injury and blood-brain barrier opening in-duced by injection of LGE2 or PGE2. Prostaglandins Leukot Essent Fatty Acids 47: 105-110, 1992.
83. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741-766, 2001.
84. Sha W and Salomon RG. Total synthesis of 17-iso-Levuglandin E4 and the structure of C22-PGF4alpha. J Org Chem 65: 5315-5326, 2000.
85. Shattock MJ and Matsuura H. Measurement of Na( + )-K+ pump current in isolated rabbit ventricular myocytes using the whole-cell voltage-clamp technique. Inhibition of the pump by oxidant stress. Circ Res 72: 91-101, 1993.
86. Spector IM. Animal longevity and protein turnover rate. Nature 249: 66, 1974.
87. Stavrovskaya IG, Baranov SV, Guo X, Davies SS, Roberts LJ, 2nd, and Kristal BS. Reactive gamma-ketoaldehydes formed via the isoprostane pathway disrupt mitochondrial respiration and calcium homeostasis. Free Radic Biol Med 49: 567-579, 2010.
88. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, and Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 81: 3883-3887, 1984.
89. Stewart WF, Kawas C, Corrada M, and Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48: 626-632, 1997.
90. Sullivan CB, Matafonova E, Roberts LJ, 2nd, Amarnath V, and Davies SS. Isoketals form cytotoxic phosphatidylethanolamine adducts in cells. J Lipid Res 51: 999-1009, 2010.
91. Tabas I. Macrophage apoptosis in atherosclerosis: consequences on plaque progression and the role of endoplasmic reticulum stress. Antioxid Redox Signal 11: 2333-2339, 2009.
92. Taglialatela G, Robinson R, and Perez-Polo JR. Inhibition of nuclear factor kappa B (NFkappaB) activity induces nerve growth factor-resistant apoptosis in PC12 cells. J Neurosci Res 47: 155-162, 1997.
93. Talati M, Meyrick B, Peebles RS, Jr., Davies SS, Dworski R, Mernaugh R, Mitchell D, Boothby M, Roberts LJ, 2nd, and Sheller JR. Oxidant stress modulates murine allergic airway responses. Free Radic Biol Med 40: 1210-1219, 2006.
94. Tong L, Thornton PL, Balazs R, and Cotman CW. Beta-amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival Is not compromised. J Biol Chem 276: 17301-17306, 2001.
95. Yang T, Wathen MS, Felipe A, Tamkun MM, Snyders DJ, and Roden DM. K+ currents and K+ channel mRNA in cultured atrial cardiac myocytes (AT-1 cells). Circ Res 75: 870-878, 1994.
96. Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, and Thurman RG. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 117: 942-952, 1999.
97. Zagol-Ikapitte I, Amarnath V, Bala M, Roberts LJ, 2nd, Oates JA, and Boutaud O. Characterization of scavengers of gamma-ketoaldehydes that do not inhibit prostaglandin biosynthesis. Chem Res Toxicol 23: 240-250, 2010.
98. Zagol-Ikapitte I, Bernoud-Hubac N, Amarnath V, Roberts LJ, 2nd, Boutaud O, and Oates JA. Characterization of bis(levuglandinyl) urea derivatives as products of the reaction between prostaglandin H2 and arginine. Biochemistry 43: 5503-5510, 2004.
99. Zagol-Ikapitte I, Masterson TS, Amarnath V, Montine TJ, Andreasson KI, Boutaud O, and Oates JA. Prostaglandin H(2)-derived adducts of proteins correlate with Alzheimer's disease severity. J Neurochem 94: 1140-1145, 2005.
100. Zagol-Ikapitte IA, Matafonova E, Amarnath V, Bodine CL, Boutaud O, Tirona RG, Oates JA, Roberts LJ, 2nd, and Davies SS. Determination of the Pharmacokinetics and Oral Bioavailability of Salicylamine, a Potent gamma-Ketoaldehyde Scavenger, by LC/MS/MS. Pharmaceutics 2: 18-29, 2010.
101. Zhang H, Hilton DA, Hanemann CO, and Zajicek J. Cannabinoid receptor and N-acyl phosphatidylethanolamine phospholipase D-evidence for altered expression in multiple sclerosis. Brain Pathol 21: 544-557, 2011.
102. Zhang W and Salomon RG. Oxidized phospholipids, isolevuglandins, and atherosclerosis. Mol Nutr Food Res 49: 1050-1062, 2005.